Pomalidomide-C8-COOH

Background Introduction

Pomalidomide-C8-COOH is a specialized E3 ligase ligand-linker conjugate commonly utilized in the design and synthesis of proteolysis targeting chimeras (PROTACs). Pomalidomide is an analog of thalidomide belonging to the class of immunomodulatory drugs (IMiDs), widely recognized for its high affinity binding to the E3 ubiquitin ligase cereblon (CRBN). The addition of an 8-carbon linker terminating in a carboxylic acid (C8-COOH) provides essential chemical flexibility for coupling with various targeting ligands, thereby enabling the development of personalized protein degradation tools.

Mechanism

The mechanism of action for Pomalidomide-C8-COOH stems from its role as a bifunctional PROTAC building block. The pomalidomide moiety binds with high specificity to the CRBN E3 ubiquitin ligase, while the C8-COOH linker offers a reactive site for conjugation with ligands that target proteins of interest. When incorporated into a PROTAC molecule, this conjugate facilitates the induced proximity between the E3 ligase and the target protein. This triggers ubiquitination of the target protein, marking it for subsequent degradation by the 26S proteasome, thus providing a powerful strategy for selective and efficient protein knockdown.

Applications

Pomalidomide-C8-COOH is extensively used in both academic and industrial research settings for the development of next-generation PROTACs. Key applications include the design of custom protein degraders for validation of novel drug targets, generation of tool compounds for mechanistic biology studies, and preclinical evaluation of PROTAC efficacy in oncology, immunology, and neurodegenerative disease models. Its robust ability to recruit CRBN and support linker attachment makes it a preferred intermediate in high-throughput screening and structure-activity relationship (SAR) studies for targeted protein degradation therapies.

The Pomalidomide-C8-COOH E3 Ligase Ligand-Linker Conjugate is a versatile tool in the development of PROTACs, enhancing targeted protein degradation through its unique structural attributes. It facilitates efficient ubiquitination and subsequent proteasomal degradation of target proteins, making it invaluable for research in drug discovery and development. The following provides a detailed description of this molecule.

Linker: The linker in Pomalidomide-C8-COOH is an aliphatic chain of eight carbon atoms, offering a moderate length that balances flexibility and rigidity. This non-cleavable linker is designed to maintain stability and ensure effective proximity between the ligand and target protein.

Ligand: The ligand component is based on pomalidomide, a thalidomide analog with a glutarimide ring structure. This ligand is known for its high affinity binding to the cereblon E3 ubiquitin ligase, a key player in targeted protein degradation pathways.

Reactive Site: The reactive site of Pomalidomide-C8-COOH is the carboxylic acid group, which couples effectively with amine-containing target protein ligands. Recommended reaction types include amide bond formation, facilitating the creation of stable PROTACs.

Recommended Target Protein Ligand: The ideal warhead for this molecule is an amine-functionalized ligand, which can form a stable amide bond with the carboxylic acid group. This compatibility ensures efficient recruitment of the target protein for degradation. Such warheads are advantageous in exploring diverse protein targets, broadening the scope of potential therapeutic applications in research.